APO Research
Talk to an analyst

APO RESEARCH · REPORT

Antibody-drug Conjugate for Cancer

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Antibody-drug Conjugate for Cancer Market Outlook and Growth Opportunities 2026

2 January 2026197 pages

Choose your research edition.

Industry ResearchAntibody-drug Conjugate for Cancer Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Antibody-drug Conjugate for Cancer Industry Growth and Trends Forecast to 203289 pages · $3,450 USDMarket StructureGlobal Antibody-drug Conjugate for Cancer Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antibody-drug Conjugate for Cancer Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Antibody-drug Conjugate for Cancer Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Antibody-drug Conjugate for Cancer market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Antibody-drug Conjugate for Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Antibody-drug Conjugate for Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Antibody-drug Conjugate for Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Antibody-drug Conjugate for Cancer market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Antibody-drug Conjugate for Cancer market include Gilead Sciences, Innate Pharma, Rakuten Medical, Seagen, AstraZeneca, GSK, Pfizer, Roche and Takeda, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Antibody-drug Conjugate for Cancer market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Antibody-drug Conjugate for Cancer and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Antibody-drug Conjugate for Cancer revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Antibody-drug Conjugate for Cancer market.

Antibody-drug Conjugate for Cancer Segment by Company

Gilead Sciences

Innate Pharma

Rakuten Medical

Seagen

AstraZeneca

GSK

Pfizer

Roche

Takeda

Antibody-drug Conjugate for Cancer Segment by Type

Hematological Malignancies Drugs

Solid Tumor Drugs

Antibody-drug Conjugate for Cancer Segment by Application

Hospital

Pharmacy

Other

Antibody-drug Conjugate for Cancer Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Antibody-drug Conjugate for Cancer status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Antibody-drug Conjugate for Cancer key companies, revenue, market share, and recent developments.

3. To split the Antibody-drug Conjugate for Cancer breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Antibody-drug Conjugate for Cancer market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Antibody-drug Conjugate for Cancer significant trends, drivers, influence factors in global and regions.

6. To analyze Antibody-drug Conjugate for Cancer competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antibody-drug Conjugate for Cancer market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antibody-drug Conjugate for Cancer and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antibody-drug Conjugate for Cancer.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Antibody-drug Conjugate for Cancer industry.

Chapter 3: Detailed analysis of Antibody-drug Conjugate for Cancer company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Antibody-drug Conjugate for Cancer in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Antibody-drug Conjugate for Cancer in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Antibody-drug Conjugate for Cancer Industry Trends Table 2. Antibody-drug Conjugate for Cancer Industry Drivers Table 3. Antibody-drug Conjugate for Cancer Industry Opportunities and Challenges Table 4. Antibody-drug Conjugate for Cancer Industry Restraints Table 5. Global Antibody-drug Conjugate for Cancer Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Antibody-drug Conjugate for Cancer Revenue Share by Company (2021-2026) Table 7. Global Antibody-drug Conjugate for Cancer Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Antibody-drug Conjugate for Cancer Key Company Manufacturing Base & Headquarters Table 9. Global Antibody-drug Conjugate for Cancer Company, Product Type & Application Table 10. Global Antibody-drug Conjugate for Cancer Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Antibody-drug Conjugate for Cancer by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Hematological Malignancies Drugs Table 15. Significant Companies of Solid Tumor Drugs Table 16. Global Antibody-drug Conjugate for Cancer Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Antibody-drug Conjugate for Cancer Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Antibody-drug Conjugate for Cancer Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Antibody-drug Conjugate for Cancer Sales Value Share by Type (2021-2026) Table 20. Global Antibody-drug Conjugate for Cancer Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Hospital Table 22. Significant Companies of Pharmacy Table 23. Significant Companies of Other Table 24. Global Antibody-drug Conjugate for Cancer Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Antibody-drug Conjugate for Cancer Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Antibody-drug Conjugate for Cancer Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Antibody-drug Conjugate for Cancer Sales Value Share by Application (2021-2026) Table 28. Global Antibody-drug Conjugate for Cancer Sales Value Share by Application (2027-2032) Table 29. Global Antibody-drug Conjugate for Cancer Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Antibody-drug Conjugate for Cancer Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Antibody-drug Conjugate for Cancer Sales Value Share by Region (2021-2026) Table 32. Global Antibody-drug Conjugate for Cancer Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Antibody-drug Conjugate for Cancer Sales Value Share by Region (2027-2032) Table 34. Global Antibody-drug Conjugate for Cancer Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Antibody-drug Conjugate for Cancer Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Antibody-drug Conjugate for Cancer Sales Value Market Share by Country (2021-2026) Table 37. Global Antibody-drug Conjugate for Cancer Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Antibody-drug Conjugate for Cancer Sales Value Market Share by Country (2027-2032) Table 39. Gilead Sciences Company Information Table 40. Gilead Sciences Business Overview Table 41. Gilead Sciences Antibody-drug Conjugate for Cancer Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Gilead Sciences Antibody-drug Conjugate for Cancer Product Portfolio Table 43. Gilead Sciences Recent Development Table 44. Innate Pharma Company Information Table 45. Innate Pharma Business Overview Table 46. Innate Pharma Antibody-drug Conjugate for Cancer Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Innate Pharma Antibody-drug Conjugate for Cancer Product Portfolio Table 48. Innate Pharma Recent Development Table 49. Rakuten Medical Company Information Table 50. Rakuten Medical Business Overview Table 51. Rakuten Medical Antibody-drug Conjugate for Cancer Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Rakuten Medical Antibody-drug Conjugate for Cancer Product Portfolio Table 53. Rakuten Medical Recent Development Table 54. Seagen Company Information Table 55. Seagen Business Overview Table 56. Seagen Antibody-drug Conjugate for Cancer Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Seagen Antibody-drug Conjugate for Cancer Product Portfolio Table 58. Seagen Recent Development Table 59. AstraZeneca Company Information Table 60. AstraZeneca Business Overview Table 61. AstraZeneca Antibody-drug Conjugate for Cancer Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. AstraZeneca Antibody-drug Conjugate for Cancer Product Portfolio Table 63. AstraZeneca Recent Development Table 64. GSK Company Information Table 65. GSK Business Overview Table 66. GSK Antibody-drug Conjugate for Cancer Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. GSK Antibody-drug Conjugate for Cancer Product Portfolio Table 68. GSK Recent Development Table 69. Pfizer Company Information Table 70. Pfizer Business Overview Table 71. Pfizer Antibody-drug Conjugate for Cancer Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Pfizer Antibody-drug Conjugate for Cancer Product Portfolio Table 73. Pfizer Recent Development Table 74. Roche Company Information Table 75. Roche Business Overview Table 76. Roche Antibody-drug Conjugate for Cancer Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Roche Antibody-drug Conjugate for Cancer Product Portfolio Table 78. Roche Recent Development Table 79. Takeda Company Information Table 80. Takeda Business Overview Table 81. Takeda Antibody-drug Conjugate for Cancer Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Takeda Antibody-drug Conjugate for Cancer Product Portfolio Table 83. Takeda Recent Development Table 84. Research Programs/Design for This Report Table 85. Authors List of This Report Table 86. Secondary Sources Table 87. Primary Sources List of Figures Figure 1. Antibody-drug Conjugate for Cancer Product Image Figure 2. Global Antibody-drug Conjugate for Cancer Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Antibody-drug Conjugate for Cancer Market Size (2021-2032) & (US$ Million) Figure 4. Global Antibody-drug Conjugate for Cancer Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Hematological Malignancies Drugs Image Figure 8. Solid Tumor Drugs Image Figure 9. Global Antibody-drug Conjugate for Cancer Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Antibody-drug Conjugate for Cancer Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Antibody-drug Conjugate for Cancer Sales Value Share by Type (2021-2032) Figure 12. Hospital Image Figure 13. Pharmacy Image Figure 14. Other Image Figure 15. Global Antibody-drug Conjugate for Cancer Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Antibody-drug Conjugate for Cancer Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Antibody-drug Conjugate for Cancer Sales Value Share by Application (2021-2032) Figure 18. Global Antibody-drug Conjugate for Cancer Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Antibody-drug Conjugate for Cancer Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Antibody-drug Conjugate for Cancer Sales Value (2021-2032) & (US$ Million) Figure 21. North America Antibody-drug Conjugate for Cancer Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Antibody-drug Conjugate for Cancer Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Antibody-drug Conjugate for Cancer Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Antibody-drug Conjugate for Cancer Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Antibody-drug Conjugate for Cancer Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Antibody-drug Conjugate for Cancer Sales Value (2021-2032) & (US$ Million) Figure 27. South America Antibody-drug Conjugate for Cancer Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Antibody-drug Conjugate for Cancer Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Antibody-drug Conjugate for Cancer Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Antibody-drug Conjugate for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Antibody-drug Conjugate for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Antibody-drug Conjugate for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Antibody-drug Conjugate for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Antibody-drug Conjugate for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Antibody-drug Conjugate for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Antibody-drug Conjugate for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Antibody-drug Conjugate for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Antibody-drug Conjugate for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Antibody-drug Conjugate for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Antibody-drug Conjugate for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Antibody-drug Conjugate for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Antibody-drug Conjugate for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Antibody-drug Conjugate for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Antibody-drug Conjugate for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Antibody-drug Conjugate for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Antibody-drug Conjugate for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Antibody-drug Conjugate for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Antibody-drug Conjugate for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Antibody-drug Conjugate for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Antibody-drug Conjugate for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Antibody-drug Conjugate for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Antibody-drug Conjugate for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Antibody-drug Conjugate for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Antibody-drug Conjugate for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Antibody-drug Conjugate for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Antibody-drug Conjugate for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Antibody-drug Conjugate for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Antibody-drug Conjugate for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Antibody-drug Conjugate for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Antibody-drug Conjugate for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Antibody-drug Conjugate for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Antibody-drug Conjugate for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Antibody-drug Conjugate for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Antibody-drug Conjugate for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Antibody-drug Conjugate for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Antibody-drug Conjugate for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Antibody-drug Conjugate for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Antibody-drug Conjugate for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Antibody-drug Conjugate for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Antibody-drug Conjugate for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Antibody-drug Conjugate for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Antibody-drug Conjugate for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Antibody-drug Conjugate for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Antibody-drug Conjugate for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Antibody-drug Conjugate for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Antibody-drug Conjugate for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Antibody-drug Conjugate for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Antibody-drug Conjugate for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Antibody-drug Conjugate for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Antibody-drug Conjugate for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Antibody-drug Conjugate for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Antibody-drug Conjugate for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Antibody-drug Conjugate for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Antibody-drug Conjugate for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Antibody-drug Conjugate for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Antibody-drug Conjugate for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Antibody-drug Conjugate for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Antibody-drug Conjugate for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Antibody-drug Conjugate for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Antibody-drug Conjugate for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Antibody-drug Conjugate for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Antibody-drug Conjugate for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Antibody-drug Conjugate for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Antibody-drug Conjugate for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Antibody-drug Conjugate for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Antibody-drug Conjugate for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Antibody-drug Conjugate for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Antibody-drug Conjugate for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Antibody-drug Conjugate for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Antibody-drug Conjugate for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Antibody-drug Conjugate for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Antibody-drug Conjugate for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Antibody-drug Conjugate for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Antibody-drug Conjugate for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Antibody-drug Conjugate for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Antibody-drug Conjugate for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Antibody-drug Conjugate for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Antibody-drug Conjugate for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Antibody-drug Conjugate for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Antibody-drug Conjugate for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Antibody-drug Conjugate for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Antibody-drug Conjugate for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Antibody-drug Conjugate for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Hematological Malignancies Drugs
  • Solid Tumor Drugs
Applications
  • Hospital
  • Pharmacy
  • Other
Companies covered
  • Gilead Sciences
  • Innate Pharma
  • Rakuten Medical
  • Seagen
  • AstraZeneca
  • GSK
  • Pfizer
  • Roche
  • Takeda

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Antibody-drug Conjugate for Cancer Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Antibody-drug Conjugate for Cancer Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Antibody-drug Conjugate for Cancer Market Dynamics
  1. 2.1 Antibody-drug Conjugate for Cancer Industry Trends
  2. 2.2 Antibody-drug Conjugate for Cancer Industry Drivers
  3. 2.3 Antibody-drug Conjugate for Cancer Industry Opportunities and Challenges
  4. 2.4 Antibody-drug Conjugate for Cancer Industry Restraints
3 Antibody-drug Conjugate for Cancer Market by Company
  1. 3.1 Global Antibody-drug Conjugate for Cancer Company Revenue Ranking in 2025
  2. 3.2 Global Antibody-drug Conjugate for Cancer Revenue by Company (2021-2026)
  3. 3.3 Global Antibody-drug Conjugate for Cancer Company Ranking (2024-2026)
  4. 3.4 Global Antibody-drug Conjugate for Cancer Company Manufacturing Base and Headquarters
  5. 3.5 Global Antibody-drug Conjugate for Cancer Company Product Type and Application
  6. 3.6 Global Antibody-drug Conjugate for Cancer Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Antibody-drug Conjugate for Cancer Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Antibody-drug Conjugate for Cancer Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Antibody-drug Conjugate for Cancer Market by Type
  1. 4.1 Antibody-drug Conjugate for Cancer Type Introduction
  2. 4.1.1 Hematological Malignancies Drugs
  3. 4.1.2 Solid Tumor Drugs
  4. 4.2 Global Antibody-drug Conjugate for Cancer Sales Value by Type
  5. 4.2.1 Global Antibody-drug Conjugate for Cancer Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Antibody-drug Conjugate for Cancer Sales Value by Type (2021-2032)
  7. 4.2.3 Global Antibody-drug Conjugate for Cancer Sales Value Share by Type (2021-2032)
5 Antibody-drug Conjugate for Cancer Market by Application
  1. 5.1 Antibody-drug Conjugate for Cancer Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Pharmacy
  4. 5.1.3 Other
  5. 5.2 Global Antibody-drug Conjugate for Cancer Sales Value by Application
  6. 5.2.1 Global Antibody-drug Conjugate for Cancer Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Antibody-drug Conjugate for Cancer Sales Value by Application (2021-2032)
  8. 5.2.3 Global Antibody-drug Conjugate for Cancer Sales Value Share by Application (2021-2032)
6 Antibody-drug Conjugate for Cancer Regional Value Analysis
  1. 6.1 Global Antibody-drug Conjugate for Cancer Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Antibody-drug Conjugate for Cancer Sales Value by Region (2021-2032)
  3. 6.2.1 Global Antibody-drug Conjugate for Cancer Sales Value by Region: 2021-2026
  4. 6.2.2 Global Antibody-drug Conjugate for Cancer Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Antibody-drug Conjugate for Cancer Sales Value (2021-2032)
  7. 6.3.2 North America Antibody-drug Conjugate for Cancer Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Antibody-drug Conjugate for Cancer Sales Value (2021-2032)
  10. 6.4.2 Europe Antibody-drug Conjugate for Cancer Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Antibody-drug Conjugate for Cancer Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Antibody-drug Conjugate for Cancer Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Antibody-drug Conjugate for Cancer Sales Value (2021-2032)
  16. 6.6.2 South America Antibody-drug Conjugate for Cancer Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Antibody-drug Conjugate for Cancer Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Antibody-drug Conjugate for Cancer Sales Value Share by Country, 2025 VS 2032
7 Antibody-drug Conjugate for Cancer Country-level Value Analysis
  1. 7.1 Global Antibody-drug Conjugate for Cancer Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Antibody-drug Conjugate for Cancer Sales Value by Country (2021-2032)
  3. 7.2.1 Global Antibody-drug Conjugate for Cancer Sales Value by Country (2021-2026)
  4. 7.2.2 Global Antibody-drug Conjugate for Cancer Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Antibody-drug Conjugate for Cancer Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Antibody-drug Conjugate for Cancer Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Antibody-drug Conjugate for Cancer Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Antibody-drug Conjugate for Cancer Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Antibody-drug Conjugate for Cancer Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Antibody-drug Conjugate for Cancer Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Antibody-drug Conjugate for Cancer Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Antibody-drug Conjugate for Cancer Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Antibody-drug Conjugate for Cancer Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Antibody-drug Conjugate for Cancer Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Antibody-drug Conjugate for Cancer Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Antibody-drug Conjugate for Cancer Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Antibody-drug Conjugate for Cancer Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Antibody-drug Conjugate for Cancer Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Antibody-drug Conjugate for Cancer Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Antibody-drug Conjugate for Cancer Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Antibody-drug Conjugate for Cancer Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Antibody-drug Conjugate for Cancer Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Antibody-drug Conjugate for Cancer Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Antibody-drug Conjugate for Cancer Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Antibody-drug Conjugate for Cancer Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Antibody-drug Conjugate for Cancer Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Antibody-drug Conjugate for Cancer Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Antibody-drug Conjugate for Cancer Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Antibody-drug Conjugate for Cancer Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Antibody-drug Conjugate for Cancer Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Antibody-drug Conjugate for Cancer Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Antibody-drug Conjugate for Cancer Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Antibody-drug Conjugate for Cancer Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Antibody-drug Conjugate for Cancer Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Antibody-drug Conjugate for Cancer Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Antibody-drug Conjugate for Cancer Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Antibody-drug Conjugate for Cancer Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Antibody-drug Conjugate for Cancer Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Antibody-drug Conjugate for Cancer Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Antibody-drug Conjugate for Cancer Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Antibody-drug Conjugate for Cancer Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Antibody-drug Conjugate for Cancer Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Antibody-drug Conjugate for Cancer Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Antibody-drug Conjugate for Cancer Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Antibody-drug Conjugate for Cancer Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Antibody-drug Conjugate for Cancer Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Antibody-drug Conjugate for Cancer Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Antibody-drug Conjugate for Cancer Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Antibody-drug Conjugate for Cancer Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Antibody-drug Conjugate for Cancer Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Antibody-drug Conjugate for Cancer Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Antibody-drug Conjugate for Cancer Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Antibody-drug Conjugate for Cancer Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Antibody-drug Conjugate for Cancer Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Antibody-drug Conjugate for Cancer Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Antibody-drug Conjugate for Cancer Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Antibody-drug Conjugate for Cancer Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Antibody-drug Conjugate for Cancer Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Antibody-drug Conjugate for Cancer Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Antibody-drug Conjugate for Cancer Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Antibody-drug Conjugate for Cancer Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Antibody-drug Conjugate for Cancer Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Antibody-drug Conjugate for Cancer Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Antibody-drug Conjugate for Cancer Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Antibody-drug Conjugate for Cancer Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Antibody-drug Conjugate for Cancer Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Antibody-drug Conjugate for Cancer Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Antibody-drug Conjugate for Cancer Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Antibody-drug Conjugate for Cancer Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Antibody-drug Conjugate for Cancer Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Antibody-drug Conjugate for Cancer Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Antibody-drug Conjugate for Cancer Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Antibody-drug Conjugate for Cancer Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Antibody-drug Conjugate for Cancer Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Antibody-drug Conjugate for Cancer Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Antibody-drug Conjugate for Cancer Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Antibody-drug Conjugate for Cancer Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Antibody-drug Conjugate for Cancer Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Antibody-drug Conjugate for Cancer Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Antibody-drug Conjugate for Cancer Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Antibody-drug Conjugate for Cancer Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Antibody-drug Conjugate for Cancer Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Antibody-drug Conjugate for Cancer Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Antibody-drug Conjugate for Cancer Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Antibody-drug Conjugate for Cancer Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Antibody-drug Conjugate for Cancer Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Antibody-drug Conjugate for Cancer Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Antibody-drug Conjugate for Cancer Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Gilead Sciences
  2. 8.1.1 Gilead Sciences Company Information
  3. 8.1.2 Gilead Sciences Business Overview
  4. 8.1.3 Gilead Sciences Antibody-drug Conjugate for Cancer Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Gilead Sciences Antibody-drug Conjugate for Cancer Product Portfolio
  6. 8.1.5 Gilead Sciences Recent Developments
  7. 8.2 Innate Pharma
  8. 8.2.1 Innate Pharma Company Information
  9. 8.2.2 Innate Pharma Business Overview
  10. 8.2.3 Innate Pharma Antibody-drug Conjugate for Cancer Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Innate Pharma Antibody-drug Conjugate for Cancer Product Portfolio
  12. 8.2.5 Innate Pharma Recent Developments
  13. 8.3 Rakuten Medical
  14. 8.3.1 Rakuten Medical Company Information
  15. 8.3.2 Rakuten Medical Business Overview
  16. 8.3.3 Rakuten Medical Antibody-drug Conjugate for Cancer Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Rakuten Medical Antibody-drug Conjugate for Cancer Product Portfolio
  18. 8.3.5 Rakuten Medical Recent Developments
  19. 8.4 Seagen
  20. 8.4.1 Seagen Company Information
  21. 8.4.2 Seagen Business Overview
  22. 8.4.3 Seagen Antibody-drug Conjugate for Cancer Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Seagen Antibody-drug Conjugate for Cancer Product Portfolio
  24. 8.4.5 Seagen Recent Developments
  25. 8.5 AstraZeneca
  26. 8.5.1 AstraZeneca Company Information
  27. 8.5.2 AstraZeneca Business Overview
  28. 8.5.3 AstraZeneca Antibody-drug Conjugate for Cancer Revenue and Gross Margin (2021-2026)
  29. 8.5.4 AstraZeneca Antibody-drug Conjugate for Cancer Product Portfolio
  30. 8.5.5 AstraZeneca Recent Developments
  31. 8.6 GSK
  32. 8.6.1 GSK Company Information
  33. 8.6.2 GSK Business Overview
  34. 8.6.3 GSK Antibody-drug Conjugate for Cancer Revenue and Gross Margin (2021-2026)
  35. 8.6.4 GSK Antibody-drug Conjugate for Cancer Product Portfolio
  36. 8.6.5 GSK Recent Developments
  37. 8.7 Pfizer
  38. 8.7.1 Pfizer Company Information
  39. 8.7.2 Pfizer Business Overview
  40. 8.7.3 Pfizer Antibody-drug Conjugate for Cancer Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Pfizer Antibody-drug Conjugate for Cancer Product Portfolio
  42. 8.7.5 Pfizer Recent Developments
  43. 8.8 Roche
  44. 8.8.1 Roche Company Information
  45. 8.8.2 Roche Business Overview
  46. 8.8.3 Roche Antibody-drug Conjugate for Cancer Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Roche Antibody-drug Conjugate for Cancer Product Portfolio
  48. 8.8.5 Roche Recent Developments
  49. 8.9 Takeda
  50. 8.9.1 Takeda Company Information
  51. 8.9.2 Takeda Business Overview
  52. 8.9.3 Takeda Antibody-drug Conjugate for Cancer Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Takeda Antibody-drug Conjugate for Cancer Product Portfolio
  54. 8.9.5 Takeda Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst